Is there a test that separates them?

No single test does. Mast cell criteria rely on mediator measurements with strict sample handling, and two competing criteria sets disagree about who qualifies. Long COVID is defined clinically by persistence after infection, not by a biomarker.

Does a negative mast cell workup settle it?

Less firmly than a negative usually does. The measurements depend on samples taken close to a reaction and handled to strict requirements, so a miss on timing or handling can produce a negative that says more about the sample than about you. Two criteria sets also disagree about who qualifies. A negative narrows the field. It does not close it.

How long after an infection does this still count as long COVID?

Definitions differ between the bodies that publish them, and they use different persistence windows. That is not a technicality: it is one reason prevalence figures disagree so widely and why two clinicians can classify the same person differently. If a source quotes you a number, the definition sitting behind it is worth asking about before the number means anything.

Is it MCAS or long COVID?

By BeatSIBO editorial team · Updated August 5, 2026

At a glance

Anchored to
MCAS
Measurements during a reaction
Long COVID gut
An event in your history
Requires
MCAS
Criteria to be met
Long COVID gut
A documented infection
Timing as a clue
MCAS
Can first appear after any illness
Long COVID gut
Onset after infection narrows, not settles
Mutually exclusive
MCAS
No
Long COVID gut
No

MCAS compared with Long COVID gut, on the dimensions that separate them
Dimension	MCAS	Long COVID gut
Anchored to	Measurements during a reaction	An event in your history
Requires	Criteria to be met	A documented infection
Timing as a clue	Can first appear after any illness	Onset after infection narrows, not settles
Mutually exclusive	No	No

The one that matters: Onset after an infection narrows the field. It does not decide between these two.

This is one of the newest confusions in this area, and one of the most common. Almost none of the conversation about it existed before 2020.

What actually separates them

The short answer

Long COVID is defined by symptoms persisting after a documented infection. Mast cell activation syndrome is defined by mediator release meeting published criteria. One is anchored to an event in your history, the other to measurements taken during a reaction. They are not alternatives on the same list, which is why people increasingly carry both.

That difference matters for what each label can do for you. A time-anchored description tells a clinician when to start looking. A criteria-based description tells them what to measure. Neither, at present, tells them what will work.

Why timing is a weaker clue than it looks

The short answer

A documented infection followed by new persistent symptoms is genuinely meaningful information. But mast cell symptoms can also first become noticeable after any significant illness, and many people cannot date their onset precisely. Onset after infection narrows the field. It does not select between these two.

The honest position is that a great many people in this situation have a symptom pattern that both labels describe adequately and neither explains mechanistically.

What is not settled here

Mast cell involvement in post-viral illness has been proposed by serious researchers and is under active investigation. It is not established, and it is not something that can currently be demonstrated in an individual outside a research setting. Sites that present it as settled are ahead of the evidence, and they are usually selling something at the same time.

Why the gut is where this shows up

Both of these produce gut symptoms that are hard to distinguish from the overgrowth picture, which is why all three tend to come up together. The relevant guideline is blunt about how far symptoms can take you.

Pimentel M et al., American Journal of Gastroenterology 2020 Clinical guideline

If no single symptom can be specifically attributed to bacterial overgrowth, which does have a test, then symptom pattern is not going to sort two conditions that overlap with each other and with overgrowth simultaneously.

What to do next

Start with what is treatable rather than with which label fits. The practical value in this area is in ruling out the specific things that have clear management, and in knowing which tests can physically answer which questions before you pay for one.

Common questions

Is there a test that separates them?: No single test does. Mast cell criteria rely on mediator measurements with strict sample handling, and two competing criteria sets disagree about who qualifies. Long COVID is defined clinically by persistence after infection, not by a biomarker.
Does a negative mast cell workup settle it?: Less firmly than a negative usually does. The measurements depend on samples taken close to a reaction and handled to strict requirements, so a miss on timing or handling can produce a negative that says more about the sample than about you. Two criteria sets also disagree about who qualifies. A negative narrows the field. It does not close it.
How long after an infection does this still count as long COVID?: Definitions differ between the bodies that publish them, and they use different persistence windows. That is not a technicality: it is one reason prevalence figures disagree so widely and why two clinicians can classify the same person differently. If a source quotes you a number, the definition sitting behind it is worth asking about before the number means anything.